Loading
Liver Disease Diagnosis and Treatment · Journal article
Journal of Complementary and Integrative Medicine · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This scoping review maps evidence on Unani medical approaches to NAFLD, identifying therapeutic strategies including diet, regimen, and pharmacotherapy with reported antioxidant, hepatoprotective, and metabolic properties. The authors conclude that available evidence suggests potential benefit but explicitly state that well-designed clinical trials are required to establish safety and efficacy, indicating current evidence is insufficient for clinical recommendation.
Scoping review. Literature on NAFLD from conventional medicine and Unani medicine, including classical Unani texts and modern preclinical and clinical studies.. Intervention: Unani therapeutic approaches: ʿIlāj bi'l-Ghidhā (diet therapy), ʿIlāj bi'l-Tadbīr (regimenal therapy), and ʿIlāj bi'l-Dawā (pharmacotherapy) with single and compound formulations.
NAFLD affects nearly one-quarter of the global population and is associated with obesity, type 2 diabetes, dyslipidaemia, and metabolic syndrome Unani therapeutic approaches centre on diet therapy (ʿIlāj bi'l-Ghidhā), regimenal therapy (ʿIlāj bi'l-Tadbīr), and pharmacotherapy (ʿIlāj bi'l-Dawā) Several single and compound Unani formulations possess hepatoprotective, antioxidant, hypolipidaemic, anti-inflammatory, and hypoglycaemic properties in preclinical and clinical studies
No comparison of Unani interventions against standard pharmacotherapy or placebo in this summary Unani therapeutic approaches centre on diet therapy (ʿIlāj bi'l-Ghidhā), regimenal therapy (ʿIlāj bi'l-Tadbīr), and pharmacotherapy (ʿIlāj bi'l-Dawā)
Clinicians should note that while Unani traditional medicine describes therapeutic approaches that may have mechanistic potential (antioxidant, anti-inflammatory properties), the authors explicitly acknowledge the absence of robust clinical evidence and recommend well-designed trials before clinical adoption. Current standard care remains lifestyle modification.
A scoping review mapping evidence on Unani therapeutic approaches to NAFLD from preclinical and clinical studies, identifying potential but unproven interventions that require rigorous trials for safety and efficacy confirmation.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note that while Unani traditional medicine describes therapeutic approaches that may have mechanistic potential (antioxidant, anti-inflammatory properties), the authors explicitly acknowledge the absence of robust clinical evidence and recommend well-designed trials before clinical adoption. Current standard care remains lifestyle modification.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Non-alcoholic fatty liver disease (NAFLD) is a chronic metabolic liver disorder affecting nearly one-quarter of the global population. It is closely associated with obesity, type 2 diabetes mellitus, dyslipidaemia, and other components of metabolic syndrome, and may progress to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Despite its increasing prevalence, effective pharmacological options remain limited, and sustained lifestyle modification continues to be the cornerstone of management. In Unani medicine, conditions resembling NAFLD are described under Sū’-i-Mizāj Kabid Bārid and Waram al-Kabid Balghamī. A scoping review methodology was employed to map the breadth of available evidence on NAFLD from both conventional and Unani medical perspectives. Electronic databases PubMed, ScienceDirect, DOAJ, Google Scholar, and the AYUSH Research Portal were searched using predefined Boolean search strings. Classical Unani texts were examined manually. Unani literature describes therapeutic approaches centred on ʿ Ilāj bi’l-Ghidhā (diet therapy), ʿIlāj bi’l-Tadbīr (regimenal therapy), and ʿIlāj bi’l-Dawā (pharmacotherapy). Several single and compound formulations possessing hepatoprotective, antioxidant, hypolipidaemic, anti-inflammatory, and hypoglycaemic properties have shown potential benefits in preclinical and clinical studies. Available evidence suggests that Unani interventions may offer therapeutic benefit in NAFLD; however, well-designed clinical trials are required to establish their safety and efficacy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.